475 related articles for article (PubMed ID: 26222284)
1. pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferon-γ gene lipoplex for efficient cancer immunotherapy.
Yuba E; Kanda Y; Yoshizaki Y; Teranishi R; Harada A; Sugiura K; Izawa T; Yamate J; Sakaguchi N; Koiwai K; Kono K
Biomaterials; 2015 Oct; 67():214-24. PubMed ID: 26222284
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy.
Yoshizaki Y; Yuba E; Sakaguchi N; Koiwai K; Harada A; Kono K
Biomaterials; 2014 Sep; 35(28):8186-96. PubMed ID: 24969637
[TBL] [Abstract][Full Text] [Related]
3. Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy.
Yuba E; Tajima N; Yoshizaki Y; Harada A; Hayashi H; Kono K
Biomaterials; 2014 Mar; 35(9):3091-101. PubMed ID: 24406217
[TBL] [Abstract][Full Text] [Related]
4. pH-sensitive polymer-modified liposome-based immunity-inducing system: Effects of inclusion of cationic lipid and CpG-DNA.
Yoshizaki Y; Yuba E; Sakaguchi N; Koiwai K; Harada A; Kono K
Biomaterials; 2017 Oct; 141():272-283. PubMed ID: 28704679
[TBL] [Abstract][Full Text] [Related]
5. A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy.
Yuba E; Harada A; Sakanishi Y; Watarai S; Kono K
Biomaterials; 2013 Apr; 34(12):3042-52. PubMed ID: 23374704
[TBL] [Abstract][Full Text] [Related]
6. The application of pH-sensitive polymer-lipids to antigen delivery for cancer immunotherapy.
Yuba E; Kono Y; Harada A; Yokoyama S; Arai M; Kubo K; Kono K
Biomaterials; 2013 Jul; 34(22):5711-21. PubMed ID: 23639528
[TBL] [Abstract][Full Text] [Related]
7. Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration.
Hattori Y; Kawakami S; Lu Y; Nakamura K; Yamashita F; Hashida M
J Gene Med; 2006 Jul; 8(7):824-34. PubMed ID: 16625665
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.
Okazaki S; Iwasaki T; Yuba E; Watarai S
J Vet Med Sci; 2018 Feb; 80(2):197-204. PubMed ID: 29311431
[TBL] [Abstract][Full Text] [Related]
9. Application of pH-sensitive fusogenic polymer-modified liposomes for development of mucosal vaccines.
Watarai S; Iwase T; Tajima T; Yuba E; Kono K; Sekiya Y
Vet Immunol Immunopathol; 2014 Mar; 158(1-2):62-72. PubMed ID: 23790647
[TBL] [Abstract][Full Text] [Related]
10. Gene delivery to dendritic cells mediated by complexes of lipoplexes and pH-sensitive fusogenic polymer-modified liposomes.
Yuba E; Kojima C; Sakaguchi N; Harada A; Koiwai K; Kono K
J Control Release; 2008 Aug; 130(1):77-83. PubMed ID: 18573563
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the type of liposome involving cytokine production induced by non-CpG Lipoplex in macrophages.
Yasuda S; Yoshida H; Nishikawa M; Takakura Y
Mol Pharm; 2010 Apr; 7(2):533-42. PubMed ID: 20047296
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice.
Hattori Y; Kawakami S; Suzuki S; Yamashita F; Hashida M
Biochem Biophys Res Commun; 2004 May; 317(4):992-9. PubMed ID: 15094367
[TBL] [Abstract][Full Text] [Related]
13. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
14. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
[TBL] [Abstract][Full Text] [Related]
15. pH-Sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity.
Yuba E; Kojima C; Harada A; Tana ; Watarai S; Kono K
Biomaterials; 2010 Feb; 31(5):943-51. PubMed ID: 19850335
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model.
Sakurai F; Terada T; Maruyama M; Watanabe Y; Yamashita F; Takakura Y; Hashida M
Cancer Gene Ther; 2003 Sep; 10(9):661-8. PubMed ID: 12944985
[TBL] [Abstract][Full Text] [Related]
17. Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection.
Mandal M; Lee KD
Biochim Biophys Acta; 2002 Jun; 1563(1-2):7-17. PubMed ID: 12007619
[TBL] [Abstract][Full Text] [Related]
18. Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects.
Miura N; Akita H; Tateshita N; Nakamura T; Harashima H
Mol Ther; 2017 Apr; 25(4):1003-1013. PubMed ID: 28236573
[TBL] [Abstract][Full Text] [Related]
19. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
20. Bioactive polysaccharide-based pH-sensitive polymers for cytoplasmic delivery of antigen and activation of antigen-specific immunity.
Yuba E; Yamaguchi A; Yoshizaki Y; Harada A; Kono K
Biomaterials; 2017 Mar; 120():32-45. PubMed ID: 28027502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]